Longevity Health Holdings, Inc. (XAGE): Nasdaq/NYSE listing notice — Longevity Health receives Nasdaq delisting notice for bid-price deficiency; hearing April 15

Longevity Health Holdings, Inc.

Failed to regain $1.00 minimum bid price by March 31, 2025 compliance deadline.
Nasdaq Determination Letter (April 1) adds bid-price deficiency as additional delisting basis.
Deficiency will be considered at April 15 hearing alongside existing MVLS shortfall.
Company intends to seek extension from Nasdaq Hearings Panel; no assurance of success.
Tickers XAGE (common) and XAGEW (warrants) at risk of delisting from Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Longevity Health Holdings, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A), 5550(b)(2)

Exact text from the filing

Nasdaq Capital Market at the hearing scheduled to occur on April 15, 2025 (the “Hearing”) with respect to the Company’s inability to regain compliance with the $35 million minimum market value of listed securities required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The Determination Letter stated that the Minimum Bid Price Deficiency serves as an additional basis for delisting the Company’s securities from the Nasdaq Capital Market, and that Panel will consider the Minimum Bid Price Deficiency at the Hearing in their decisi

View on SEC.gov

Browse all listing & compliance notices →

Longevity Health Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-049943

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.